Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Series
Series
ESMO Early Breast Cancer
ADC Therapy Treatment HER2+ and HER2-Low mBC
IWTI Best Practices in GU Navigation
Antibody Drug Conjugate Therapy for the Treatment of HER2+ and HER2-Low mBC
ESMO Early Breast Cancer
Interview with the Innovators
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
Read More
ESMO Early Breast Cancer
Interview with the Innovators
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
Read More
ESMO Early Breast Cancer
Interview with the Innovators
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
Read More
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Educating on HER2-Low mBC
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Fostering Shared Treatment Decision-Making
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Setting Appropriate Patient Goals of Therapy
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Managing Patient Expectations and ADC-Related Side Effects
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Care Team and Patient Resources and Tools for mBC
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
ADC Therapy Treatment HER2+ and HER2-Low mBC
Interview with the Innovators
Assurance in ADC Therapy for HER2+ or HER2-Low mBC
Tajuana Bradley, MS, FNP-BC
,
Ryan Haumschild, PharmD, MS, MBA
,
Abbey J. Kaler, MS, APRN, FNP-C
,
Susie Ulloa, RN, OCN, ONN-CG
Read More
IWTI Best Practices in GU Navigation
Interview with the Innovators
A New Era of Treatment Options for Patients with Advanced Renal-Cell Cancer
Megan Price, MSN, APRN, FNP-C
,
Virginia Seery, MSN, RN, ANP-BC, AOCNP
,
Laura Wood, RN, MSN, OCN
Read More
1
2
3
Page 1 of 3
Results 1 - 10 of 21